Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefania Pizzimenti

Showing results (71-80 of 72) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 72 results.
Journal of Biomedical Nanotechnology|October 30, 2015
Improved Anti-Tumoral Therapeutic Efficacy of 4-Hydroxynonenal Incorporated in Novel Lipid Nanocapsules in 2D and 3D ModelsStefania Pizzimenti, Martina Daga, Eric Ciamporcero, et al.
Nature Communications|August 25, 2025
The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically activeCelia Sequera, Margherita Grattarola, Floriane Cannet, et al.
Pageof 8

Showing results (71-80 of 72) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 72 results.
Journal of Biomedical Nanotechnology|October 30, 2015
Improved Anti-Tumoral Therapeutic Efficacy of 4-Hydroxynonenal Incorporated in Novel Lipid Nanocapsules in 2D and 3D ModelsStefania Pizzimenti, Martina Daga, Eric Ciamporcero, et al.
Nature Communications|August 25, 2025
The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically activeCelia Sequera, Margherita Grattarola, Floriane Cannet, et al.
Pageof 8